The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS MSD Japan Suffers 7% Sales Dip on Repeated Keytruda Re-Pricing, Urges Policy Rethink
April 21, 2021
-
ORGANIZATION EFPIA Issues Proposals for Japanese CEA System, Says “Cannot Accept” Expansion without Corrective Steps
April 21, 2021
-
BUSINESS New Grad Hiring Down 3.3% at 55 Drug Makers, Sales Rep Opportunities Fall amid DX: Survey
April 20, 2021
-
REGULATORY MHLW to Revoke Approval of 12 Kobayashi Kako Products as Documents Fabricated
April 19, 2021
-
ORGANIZATION Scandals Making It Difficult to Recommend Generics to Members: Kyokai Kenpo Chair
April 16, 2021
-
REGULATORY Olumiant Up for PAFSC Review for COVID-19 on April 21, Combo Use with Veklury
April 15, 2021
-
BUSINESS Lilly Japan Set for Leading Spot in All Core Areas in 2025, “No Plan to Replicate” Redundancy Program: Chief
April 14, 2021
-
REGULATORY 11 APIs to Get NHI Price Listing on April 21, 17 Billion Yen Peak Sales Projected for Lilly’s Migraine Med
April 14, 2021
-
REGULATORY Kymriah to Face 4% Price Cut in 1st CEA-Based Price Tweak, Yescarta Too
April 13, 2021
-
BUSINESS Novo Japan Notches 10% Growth in 2020, President Proud of This Feat amid Market Decline
April 13, 2021
-
BUSINESS Maruho Aspires to Get Back on Growth Track on New Drug Launches: President
April 12, 2021
-
BUSINESS Kobayashi Kako’s Seima Factory Operations Still Halted Even after 60-Day Order Lifted
April 12, 2021
-
ORGANIZATION Wakayama Council Makes List of 500 Drugs Commonly Used in Region, Snubs Nichi-Iko/Kobayashi Kako Generics
April 9, 2021
-
BUSINESS Nichi-Iko Recalls 2 Products over Quality Issues Days after Biz Suspension Lifted
April 9, 2021
-
BUSINESS Teijin Pharma Set to Transform Biz, Weather Feburic Patent Cliff with Takeda’s DPP-4s
April 8, 2021
-
BUSINESS Astellas Ended Scholarship Donation to Clear Up Doubts on Inducing Prescriptions, No Major Issues Seen after 1 Year
April 8, 2021
-
BUSINESS Takeda Sees FY2021 as Inflection Year for Pipeline, 4 Potential Approvals from 6 Submission-Planned Assets
April 7, 2021
-
BUSINESS AstraZeneca Looks to Become Top Drug Maker in Japan by 2025
April 7, 2021
-
REGULATORY AMED to Set Up Council to Hone Academic Seeds with Industry Input
April 7, 2021
-
BUSINESS Daiichi Sankyo Looks to Rack Up Sales of 1.6 Trillion Yen in FY2025, 3 ADCs as Drivers
April 6, 2021
ページ
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…